Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.

ABSTRACT:

Background

Mismatch repair (MMR) system has been implicated in the response of mammalian cells to ionizing radiation and DNA damaging agents. We investigated the value of the MMR system in predicting response to adjuvant therapy in endometrial cancer.

Methods

This was a single institution retrospective study. MMR protein status of endometrial carcinomas was assessed by immunohistochemistry. MMR deficient (MMR-D) tumors were identified as MLH1 methylated or nonmethylated by methylation-specific multiplex ligation-dependent probe amplification. Tumors with abnormal p53 staining or polymerase ϵ exonuclease domain mutation were excluded from the MMR proficient subgroup, which was termed as "no specific molecular profile" (NSMP). Disease-specific survival analyses were adjusted f

SUBMITTER: Loukovaara M 

PROVIDER: S-EPMC7897956 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature